Results 141 to 150 of about 9,431 (199)
Diagnostic and therapeutic applications of the glycan biomarker H3N2b in GM1 Gangliosidosis. [PDF]
Kell P +14 more
europepmc +1 more source
Mapping Sanfilippo Syndrome: A Multisystem Clinicopathological Autopsy. [PDF]
Trandafirescu MF +9 more
europepmc +1 more source
[Case of mucopolysaccharidosis II--Hunter's syndrome].
M, Walczak +3 more
openaire +1 more source
Assessment of bone health and bone mineral density in patients with mucopolysaccharidosis receiving enzyme replacement therapy. [PDF]
El Feil NSA, Abuzaid Y, Mobarak A.
europepmc +1 more source
Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB. [PDF]
Wijnen M +5 more
europepmc +1 more source
Newborn Screening and Early Cord Blood Transplant for Mucopolysaccharidosis.
Sakaguchi H +18 more
europepmc +1 more source
Audiologic evaluations of children with mucopolysaccharidosis [PDF]
INTRODUCTION: Mucopolysaccharidosis is a hereditary lysosomal storage disease, which develops due to a deficiency in the enzymes that play a role in the metabolism of glycosaminoglycans (GAG).
Håkan Tutar +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nasal Polyposis in mucopolysaccharidosis type II
BMJ Case Reports, 2021Mucopolysaccharidosis (MPS) type II is a rare multisystem disorder resulting from the accumulation of breakdown products of glycosaminoglycans in the body tissues. Many patients with this disease undergo ENT (ear, nose and throat) surgeries such as adenotonsillectomy and tympanocentesis at a very early age, much before the diagnosis of MPS.
Sushmitha Kabekkodu +3 more
openaire +2 more sources

